203 related articles for article (PubMed ID: 11723856)
21. [Restoration of the quality of life by eliminating and prevention of heartburn by alginate: results of multicenter study "VIA APIA"].
Lazebnik LB; Bordin DS; Masharova AA; Dzhulaĭ GS; Butov MA; Abdulkhakov RA; Eremina EIu; Tarasova LV; Safonova OV; Firsova LD; Kozhurina TS
Eksp Klin Gastroenterol; 2010; (6):70-6. PubMed ID: 20731169
[TBL] [Abstract][Full Text] [Related]
22. [Gastroesophageal reflux disease during pregnancy].
Elokhina TB; Tiutiunnik VL
Eksp Klin Gastroenterol; 2009; (3):93-7. PubMed ID: 19928006
[No Abstract] [Full Text] [Related]
23. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children.
Buts JP; Barudi C; Otte JB
Eur J Pediatr; 1987 Mar; 146(2):156-8. PubMed ID: 3032640
[TBL] [Abstract][Full Text] [Related]
24. Effect of alginate in patients with GERD hiatal hernia matters.
Vardar R; Keskin M; Valitova E; Bayrakci B; Yildirim E; Bor S
Dis Esophagus; 2017 Oct; 30(10):1-7. PubMed ID: 28859383
[TBL] [Abstract][Full Text] [Related]
25. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy.
Lindow SW; Regnéll P; Sykes J; Little S
Int J Clin Pract; 2003 Apr; 57(3):175-9. PubMed ID: 12723718
[TBL] [Abstract][Full Text] [Related]
26. Algicon in the management of gastro-oesophageal reflux.
Lambert JR; Korman MG; Nicholson L
Br J Clin Pract Suppl; 1989 Feb; 66():56-8; discussion 61-4. PubMed ID: 2556177
[No Abstract] [Full Text] [Related]
27. Sodium Alginate (Gaviscon®) does not reduce apnoeas related to gastro-oesophageal reflux in preterm infants.
Corvaglia L; Spizzichino M; Zama D; Aceti A; Mariani E; Legnani E; Faldella G
Early Hum Dev; 2011 Dec; 87(12):775-8. PubMed ID: 21696897
[TBL] [Abstract][Full Text] [Related]
28. [Multicenter study of sodium alginate in the treatment of regurgitation in infants].
Le Luyer B; Mougenot JF; Mashako L; Chapoy P; Olives JP; Morali A; Chevallier B; Ginies JL; Dupont C; Dagorne M
Ann Pediatr (Paris); 1992 Dec; 39(10):635-40. PubMed ID: 1485782
[TBL] [Abstract][Full Text] [Related]
29. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.
Mandel KG; Daggy BP; Brodie DA; Jacoby HI
Aliment Pharmacol Ther; 2000 Jun; 14(6):669-90. PubMed ID: 10848650
[TBL] [Abstract][Full Text] [Related]
30. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children.
Forbes D; Hodgson M; Hill R
J Pediatr Gastroenterol Nutr; 1986; 5(4):556-9. PubMed ID: 3016226
[TBL] [Abstract][Full Text] [Related]
31. [Gastroesophageal reflux. Results of a multicenter study of 170 patients on the therapeutic value of the Gaviscon drinkable suspension].
Chevrel B
Med Chir Dig; 1980; 9(6):535-9. PubMed ID: 6259459
[No Abstract] [Full Text] [Related]
32. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
[TBL] [Abstract][Full Text] [Related]
33. Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper.
Deraman MA; Abdul Hafidz MI; Lawenko RM; Ma ZF; Wong MS; Coyle C; Lee YY
Aliment Pharmacol Ther; 2020 Jun; 51(11):1014-1021. PubMed ID: 32343001
[TBL] [Abstract][Full Text] [Related]
34. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease.
Chatfield S
Curr Med Res Opin; 1999; 15(3):152-9. PubMed ID: 10621921
[TBL] [Abstract][Full Text] [Related]
35. Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).
Wilkinson J; Abd-Elaziz K; den Daas I; Wemer J; van Haastert M; Hodgkinson V; Foster M; Coyle C
Drug Dev Ind Pharm; 2019 Mar; 45(3):430-438. PubMed ID: 30470147
[TBL] [Abstract][Full Text] [Related]
36. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
[TBL] [Abstract][Full Text] [Related]
37. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study.
De Ruigh A; Roman S; Chen J; Pandolfino JE; Kahrilas PJ
Aliment Pharmacol Ther; 2014 Sep; 40(5):531-7. PubMed ID: 25041141
[TBL] [Abstract][Full Text] [Related]
38. [Esophageal reflux and peptic ulcer. An exclusive advanced education service of the Gastro-Liga for family physicians].
Fortschr Med; 1998 Dec; 116(34):35-8. PubMed ID: 10024760
[No Abstract] [Full Text] [Related]
39. [Therapeutic procedures in gastroesophageal reflux disease].
Tytgat GN
Z Gastroenterol; 1986 Sep; 24 Suppl 2():40-4. PubMed ID: 2877526
[TBL] [Abstract][Full Text] [Related]
40. Patterns of food and acid reflux in patients with low-grade oesophagitis--the role of an anti-reflux agent.
Washington N; Steele RJ; Jackson SJ; Washington C; Bush D
Aliment Pharmacol Ther; 1998 Jan; 12(1):53-8. PubMed ID: 9692701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
